“We believe that subcutaneous formulation has the potential to be novel, non-obvious and useful, which means we would get a new patent for it,” according to Merck CFO Caroline Litchfield.
https://www.pharmalive.com/wp-content/uploads/2021/06/U.S.-signs-1.2-bln-deal-for-1.7-mln-courses-of-Mercks-experimental-COVID-19-drug-Reuters-6-9-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-12-02 07:04:522022-12-02 09:06:21Merck could keep its patent edge by shifting Keytruda cancer drug to a simple shot